Martin S Wolpoff Net Worth

The estimated Net Worth of Martin S Wolpoff is at least $83.4 Tisíc dollars as of 3 June 2009. Martin Wolpoff owns over 1,000 units of Daxor stock worth over $36,560 and over the last 20 years Martin sold DXR stock worth over $46,860.

Martin Wolpoff DXR stock SEC Form 4 insiders trading

Martin has made over 8 trades of the Daxor stock since 2008, according to the Form 4 filled with the SEC. Most recently Martin bought 1,000 units of DXR stock worth $10,480 on 3 June 2009.

The largest trade Martin's ever made was selling 3,000 units of Daxor stock on 17 November 2008 worth over $46,860. On average, Martin trades about 700 units every 20 days since 2004. As of 3 June 2009 Martin still owns at least 4,000 units of Daxor stock.

You can see the complete history of Martin Wolpoff stock trades at the bottom of the page.

What's Martin Wolpoff's mailing address?

Martin's mailing address filed with the SEC is DAXOR CORPORATION, 350 FIFTH AVE, STE 4740, NEW YORK, NY, 10118.

Insiders trading at Daxor

Over the last 21 years, insiders at Daxor have traded over $7,541,627 worth of Daxor stock and bought 473,408 units worth $2,888,339 . The most active insiders traders include Joseph Feldschuh, Bruce Slovin a Robert J Michel. On average, Daxor executives and independent directors trade stock every 39 days with the average trade being worth of $27,740. The most recent stock trade was executed by Robert J Michel on 27 March 2024, trading 750 units of DXR stock currently worth $6,525.

What does Daxor do?

the bva-100 (blood volume analyzer) is the first instrument of its kind that can precisely measure the amount of blood a patient has in their body. blood volume measurements have been available for almost 60 years, but the test often took 4 to 8 hours to perform and was very difficult to perform accurately. due to these issues, blood volume measurements were very rarely done. physicians had been forced to rely on substitute tests that were only able to measure the thickness of the blood and can be very misleading in many surgical and medical situations. the bva-100 can measure blood volume: accurately, quickly & reliably.

Complete history of Martin Wolpoff stock trades at Daxor

Daxor executives and stock owners

Daxor executives and other stock owners filed with the SEC include:

• Jonathan Adam Feldschuh,
  Chief Scientific Officer & Director
• Michael Richard Feldschuh,
  Chairman, Pres & CEO
• Diane Meegan,
  IR Contact Officer
• Robert Willens,
  Independent Director
• James Lombard,
  Independent Director
• Joy Goudie,
  Independent Director
• Edward Feuer,
  Director
• Henry Cremisi,
  Director
• Jonathan Feldschuh,
  Chief Scientific Officer, Director
• Robert Michel,
  Chief Financial Officer
• Michael Feldschuh,
  Chairman of the Board, President, Chief Executive Officer
• Robert J. Michel M.B.A., CPA, CPA,
  CFO, Chief Compliance Officer & Corp. Sec.
• Guido Manzo,
  VP of Sales
• Kathryn A. Kornafel,
  VP of Marketing & Commercial Devel.
• Robert J. Michel M.B.A., C.P.A., CPA,
  CFO, Chief Compliance Officer & Corp. Sec.
• Caleb Des Rosiers,
  Director
• Of Joseph Feldschuh Estate,
  10% owner
• Bernhard Saxe,
  Director
• Soren Thompson,
  VP, Business Development
• Everis Engstrom,
  Vice President
• Robert G Moussa,
  Director
• Martin S Wolpoff,
  Director
• Philip Nordan Hudson,
  Director
• Joseph Feldschuh,
  President & CEO
• Stephen Valentine,
  Director
• Bruce Slovin,
  Director
• Gary Joseph Fischman,
  President